TY - JOUR T1 - Single-strand RPA for rapid and sensitive detection of SARS-CoV-2 RNA JF - medRxiv DO - 10.1101/2020.08.17.20177006 SP - 2020.08.17.20177006 AU - Youngeun Kim AU - Adam B. Yaseen AU - Jocelyn Y. Kishi AU - Fan Hong AU - Sinem K. Saka AU - Kuanwei Sheng AU - Nikhil Gopalkrishnan AU - Thomas E. Schaus AU - Peng Yin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/21/2020.08.17.20177006.abstract N2 - We report the single-strand Recombinase Polymerase Amplification (ssRPA) method, which merges the fast, isothermal amplification of RPA with subsequent rapid conversion of the double-strand DNA amplicon to single strands, and hence enables facile hybridization-based, high-specificity readout. We demonstrate the utility of ssRPA for sensitive and rapid (4 copies per 50 µL reaction within 10 min, or 8 copies within 8 min) visual detection of SARS-CoV-2 RNA spiked samples, as well as clinical saliva and nasopharyngeal swabs in VTM or water, on lateral flow devices. The ssRPA method promises rapid, sensitive, and accessible RNA detection to facilitate mass testing in the COVID-19 pandemic.Competing Interest StatementThe authors have applied for patents based on the work. P.Y. is a co-founder and director of Ultivue, Inc., NuProbe Global, and Torus Biosystems, Inc.Funding StatementWe acknowledge support from NIH 1DP1GM133052-01 and the Wyss Institute Molecular Robotics Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of the Harvard Faculty of Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are included within the manuscript and supplemental information. Please contact corresponding authors for more information. ER -